secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001654954-24-010399
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA CEO Michelon resigns; board member Tokman named acting CEO, new CFO and regulatory head appointed
--------------------------------------------------------------------------------

- Francois Michelon stepped down as CEO and board member effective Aug 12, 2024; separation includes 4 months' salary and 12 months' healthcare coverage.
- Alexander Tokman, board member since 2008, appointed acting CEO and Chairman effective Aug 13, 2024; Tokman has 24+ years of commercial leadership and prior GE Healthcare executive experience.
- Ziad Rouag appointed Head of Regulatory and Clinical Affairs; Richard Jacroux appointed CFO; Irina Pestrikova to transition and remain advisor.
- Tokman will focus on regulatory approval and commercial launch of TAEUS system with strict fiscal discipline.
- No disagreement involved in Michelon's resignation; separation agreement includes release of claims and termination of restrictive covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424010399/0001654954-24-010399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424010399/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-010399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer